Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Pros...
Vir Biotechnology reported Phase 1 results showing acceptable safety and preliminary anti-tumor activity for VIR-5500, a PSMA-targeting PRO-XTEN dual-masked T-cell engager, in patients with metastatic prostate cancer.
Why it mattersPhase 1 VIR-5500 data in metastatic prostate cancer suggest shifting early R&D and investment toward PSMA-directed T-cell engagers.